Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
RCUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.82 - $19.11
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.24M
Market Cap
$946.22M
Enterprise Value$366.51M
Total Cash (Recent Filing)$71.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.90
Next Earnings
May 13, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding105,841,420
10 Day Avg. Volume1,033,080
30 Day Avg. Volume1,241,357
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.42
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$31.00Price Target Upside239.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Arcus Biosciences News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe outcomes from ARC-20 at ASCO-GU provide a compelling signal that casdatifan has a distinct advantage over market leader belzutifan.
Financial PositionRCUS finished 2024 in a strong cash position, with $992M in cash and cash equivalents expected to fund operations into mid-2027.
Stock ValuationThe current stock levels are viewed as an attractive entry point, supporting the upgrade to Buy from Neutral.
Bears Say
Investor ConcernsInvestors have expressed hesitation stemming from Gilead’s decision not to opt-in to the program and whether cas’s differentiation over Merck’s belzutifan will prove clinically meaningful.
Partnership DecisionsGILD chose not to opt-in for commercial rights to cas, driven by strategic concerns.
---
Ownership Overview
6.46% Insiders
15.23% Mutual Funds
51.34% Other Institutional Investors
11.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $8.82 and its highest was $19.11 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Arcus Biosciences Inc’s market cap is $946.22M.
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Feb 25, 2025. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.249 by $0.219.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -1.02.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 105,841,420 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.249. Following the earnings report the stock price went down -0.977%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Currently, no hedge funds are holding shares in RCUS
---
Arcus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (239.91% Upside)
$31.00 (239.91% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 11.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.49%
12-Months-Change
Fundamentals
Return on Equity
-59.77%
Trailing 12-Months
Asset Growth
5.02%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
---
RCUS Company Deck
---
RCUS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong data for key drug candidates, significant progress in clinical trials, and a stable financial position, although strategic uncertainties with collaborations and competitive challenges in the RCC market were noted.Read More>---
RCUS Stock 12 Month Forecast
Average Price Target
$31.00
▲(239.91% Upside)
Technical Analysis
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-18.74%
reiterated a buy rating 29 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -18.74% per trade.
---